Global Cancer Angiogenesis Inhibitors market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. Get access now!

Global Cancer Angiogenesis Inhibitors Market Trends and Opportunities 2025-31

The global Cancer Angiogenesis Inhibitors market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031. The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report. According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment. Infinity Market Research newest research report, the Cancer Angiogenesis Inhibitors Industry Forecast looks at past sales and reviews total world Cancer Angiogenesis Inhibitors sales in 2024, providing a comprehensive analysis by region and market sector of projected Cancer Angiogenesis Inhibitors sales for 2025 through 2031. With Cancer Angiogenesis Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Cancer Angiogenesis Inhibitors industry. This Insight Report provides a comprehensive analysis of the global Cancer Angiogenesis Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Cancer Angiogenesis Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms unique position in an accelerating global Cancer Angiogenesis Inhibitors market. This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Cancer Angiogenesis Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Cancer Angiogenesis Inhibitors. This report presents a comprehensive overview, market shares, and growth opportunities of Cancer Angiogenesis Inhibitors market by product type, application, key manufacturers and key regions and countries. Segmentation by Type: &nbsp;&nbsp;&nbsp; VEGF Targeted Therapy &nbsp;&nbsp;&nbsp; FGF Targeted Therapies &nbsp;&nbsp;&nbsp; Oncogene Targeted Therapy &nbsp;&nbsp;&nbsp; Matrix Degrading & Remodeling Targeted Therapy &nbsp;&nbsp;&nbsp; Others Segmentation by Application: &nbsp;&nbsp;&nbsp; Cancer &nbsp;&nbsp;&nbsp; Interferon Alpha-2? &nbsp;&nbsp;&nbsp; Ocular Neovascularization This report also splits the market by region: &nbsp;&nbsp;&nbsp; Americas &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; United States &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Canada &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mexico &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Brazil &nbsp;&nbsp;&nbsp; APAC &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; China &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Japan &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Korea &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Southeast Asia &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; India &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Australia &nbsp;&nbsp;&nbsp; Europe &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Germany &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; France &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UK &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Italy &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Russia &nbsp;&nbsp;&nbsp; Middle East & Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Egypt &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; South Africa &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Israel &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Turkey &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; GCC Countries The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the companys coverage, product portfolio, its market penetration. &nbsp;&nbsp;&nbsp; Intas Pharmaceuticals &nbsp;&nbsp;&nbsp; Kyowa Hakko Kirin &nbsp;&nbsp;&nbsp; Levolta Pharmaceuticals &nbsp;&nbsp;&nbsp; Mabtech &nbsp;&nbsp;&nbsp; Marsala Biotech &nbsp;&nbsp;&nbsp; Neumedicines &nbsp;&nbsp;&nbsp; Genentech &nbsp;&nbsp;&nbsp; Five Prime Therapeutics &nbsp;&nbsp;&nbsp; Fuji Film Kyowa Kirin Biologics &nbsp;&nbsp;&nbsp; Genexine &nbsp;&nbsp;&nbsp; Hetero Drugs &nbsp;&nbsp;&nbsp; ImClone Systems &nbsp;&nbsp;&nbsp; Novartis Key Questions Addressed in this Report What is the 10-year outlook for the global Cancer Angiogenesis Inhibitors market? What factors are driving Cancer Angiogenesis Inhibitors market growth, globally and by region? Which technologies are poised for the fastest growth by market and region? How do Cancer Angiogenesis Inhibitors market opportunities vary by end market size? How does Cancer Angiogenesis Inhibitors break out by Type, by Application?

1 Scope of the Report &nbsp;1.1 Market Introduction &nbsp;1.2 Years Considered &nbsp;1.3 Research Objectives &nbsp;1.4 Market Research Methodology &nbsp;1.5 Research Process and Data Source &nbsp;1.6 Economic Indicators &nbsp;1.7 Currency Considered &nbsp;1.8 Market Estimation Caveats 2 Executive Summary &nbsp;2.1 World Market Overview &nbsp;2.1.1 Global Cancer Angiogenesis Inhibitors Annual Sales 2020-2031 &nbsp;2.1.2 World Current & Future Analysis for Cancer Angiogenesis Inhibitors by Geographic Region, 2020, 2024 & 2031 &nbsp;2.1.3 World Current & Future Analysis for Cancer Angiogenesis Inhibitors by Country/Region, 2020, 2024 & 2031 &nbsp;2.2 Cancer Angiogenesis Inhibitors Segment by Type &nbsp;2.2.1 VEGF Targeted Therapy &nbsp;2.2.2 FGF Targeted Therapies &nbsp;2.2.3 Oncogene Targeted Therapy &nbsp;2.2.4 Matrix Degrading & Remodeling Targeted Therapy &nbsp;2.2.5 Others &nbsp;2.3 Cancer Angiogenesis Inhibitors Sales by Type &nbsp;2.3.1 Global Cancer Angiogenesis Inhibitors Sales Market Share by Type (2020-2025) &nbsp;2.3.2 Global Cancer Angiogenesis Inhibitors Revenue and Market Share by Type (2020-2025) &nbsp;2.3.3 Global Cancer Angiogenesis Inhibitors Sale Price by Type (2020-2025) &nbsp;2.4 Cancer Angiogenesis Inhibitors Segment by Application &nbsp;2.4.1 Cancer &nbsp;2.4.2 Interferon Alpha-2? &nbsp;2.4.3 Ocular Neovascularization &nbsp;2.5 Cancer Angiogenesis Inhibitors Sales by Application &nbsp;2.5.1 Global Cancer Angiogenesis Inhibitors Sale Market Share by Application (2020-2025) &nbsp;2.5.2 Global Cancer Angiogenesis Inhibitors Revenue and Market Share by Application (2020-2025) &nbsp;2.5.3 Global Cancer Angiogenesis Inhibitors Sale Price by Application (2020-2025) 3 Global by Company &nbsp;3.1 Global Cancer Angiogenesis Inhibitors Breakdown Data by Company &nbsp;3.1.1 Global Cancer Angiogenesis Inhibitors Annual Sales by Company (2020-2025) &nbsp;3.1.2 Global Cancer Angiogenesis Inhibitors Sales Market Share by Company (2020-2025) &nbsp;3.2 Global Cancer Angiogenesis Inhibitors Annual Revenue by Company (2020-2025) &nbsp;3.2.1 Global Cancer Angiogenesis Inhibitors Revenue by Company (2020-2025) &nbsp;3.2.2 Global Cancer Angiogenesis Inhibitors Revenue Market Share by Company (2020-2025) &nbsp;3.3 Global Cancer Angiogenesis Inhibitors Sale Price by Company &nbsp;3.4 Key Manufacturers Cancer Angiogenesis Inhibitors Producing Area Distribution, Sales Area, Product Type &nbsp;3.4.1 Key Manufacturers Cancer Angiogenesis Inhibitors Product Location Distribution &nbsp;3.4.2 Players Cancer Angiogenesis Inhibitors Products Offered &nbsp;3.5 Market Concentration Rate Analysis &nbsp;3.5.1 Competition Landscape Analysis &nbsp;3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025) &nbsp;3.6 New Products and Potential Entrants &nbsp;3.7 Market M&A Activity & Strategy 4 World Historic Review for Cancer Angiogenesis Inhibitors by Geographic Region &nbsp;4.1 World Historic Cancer Angiogenesis Inhibitors Market Size by Geographic Region (2020-2025) &nbsp;4.1.1 Global Cancer Angiogenesis Inhibitors Annual Sales by Geographic Region (2020-2025) &nbsp;4.1.2 Global Cancer Angiogenesis Inhibitors Annual Revenue by Geographic Region (2020-2025) &nbsp;4.2 World Historic Cancer Angiogenesis Inhibitors Market Size by Country/Region (2020-2025) &nbsp;4.2.1 Global Cancer Angiogenesis Inhibitors Annual Sales by Country/Region (2020-2025) &nbsp;4.2.2 Global Cancer Angiogenesis Inhibitors Annual Revenue by Country/Region (2020-2025) &nbsp;4.3 Americas Cancer Angiogenesis Inhibitors Sales Growth &nbsp;4.4 APAC Cancer Angiogenesis Inhibitors Sales Growth &nbsp;4.5 Europe Cancer Angiogenesis Inhibitors Sales Growth &nbsp;4.6 Middle East & Africa Cancer Angiogenesis Inhibitors Sales Growth 5 Americas &nbsp;5.1 Americas Cancer Angiogenesis Inhibitors Sales by Country &nbsp;5.1.1 Americas Cancer Angiogenesis Inhibitors Sales by Country (2020-2025) &nbsp;5.1.2 Americas Cancer Angiogenesis Inhibitors Revenue by Country (2020-2025) &nbsp;5.2 Americas Cancer Angiogenesis Inhibitors Sales by Type (2020-2025) &nbsp;5.3 Americas Cancer Angiogenesis Inhibitors Sales by Application (2020-2025) &nbsp;5.4 United States &nbsp;5.5 Canada &nbsp;5.6 Mexico &nbsp;5.7 Brazil 6 APAC &nbsp;6.1 APAC Cancer Angiogenesis Inhibitors Sales by Region &nbsp;6.1.1 APAC Cancer Angiogenesis Inhibitors Sales by Region (2020-2025) &nbsp;6.1.2 APAC Cancer Angiogenesis Inhibitors Revenue by Region (2020-2025) &nbsp;6.2 APAC Cancer Angiogenesis Inhibitors Sales by Type (2020-2025) &nbsp;6.3 APAC Cancer Angiogenesis Inhibitors Sales by Application (2020-2025) &nbsp;6.4 China &nbsp;6.5 Japan &nbsp;6.6 South Korea &nbsp;6.7 Southeast Asia &nbsp;6.8 India &nbsp;6.9 Australia &nbsp;6.10 China Taiwan 7 Europe &nbsp;7.1 Europe Cancer Angiogenesis Inhibitors by Country &nbsp;7.1.1 Europe Cancer Angiogenesis Inhibitors Sales by Country (2020-2025) &nbsp;7.1.2 Europe Cancer Angiogenesis Inhibitors Revenue by Country (2020-2025) &nbsp;7.2 Europe Cancer Angiogenesis Inhibitors Sales by Type (2020-2025) &nbsp;7.3 Europe Cancer Angiogenesis Inhibitors Sales by Application (2020-2025) &nbsp;7.4 Germany &nbsp;7.5 France &nbsp;7.6 UK &nbsp;7.7 Italy &nbsp;7.8 Russia 8 Middle East & Africa &nbsp;8.1 Middle East & Africa Cancer Angiogenesis Inhibitors by Country &nbsp;8.1.1 Middle East & Africa Cancer Angiogenesis Inhibitors Sales by Country (2020-2025) &nbsp;8.1.2 Middle East & Africa Cancer Angiogenesis Inhibitors Revenue by Country (2020-2025) &nbsp;8.2 Middle East & Africa Cancer Angiogenesis Inhibitors Sales by Type (2020-2025) &nbsp;8.3 Middle East & Africa Cancer Angiogenesis Inhibitors Sales by Application (2020-2025) &nbsp;8.4 Egypt &nbsp;8.5 South Africa &nbsp;8.6 Israel &nbsp;8.7 Turkey &nbsp;8.8 GCC Countries 9 Market Drivers, Challenges and Trends &nbsp;9.1 Market Drivers & Growth Opportunities &nbsp;9.2 Market Challenges & Risks &nbsp;9.3 Industry Trends 10 Manufacturing Cost Structure Analysis &nbsp;10.1 Raw Material and Suppliers &nbsp;10.2 Manufacturing Cost Structure Analysis of Cancer Angiogenesis Inhibitors &nbsp;10.3 Manufacturing Process Analysis of Cancer Angiogenesis Inhibitors &nbsp;10.4 Industry Chain Structure of Cancer Angiogenesis Inhibitors 11 Marketing, Distributors and Customer &nbsp;11.1 Sales Channel &nbsp;11.1.1 Direct Channels &nbsp;11.1.2 Indirect Channels &nbsp;11.2 Cancer Angiogenesis Inhibitors Distributors &nbsp;11.3 Cancer Angiogenesis Inhibitors Customer 12 World Forecast Review for Cancer Angiogenesis Inhibitors by Geographic Region &nbsp;12.1 Global Cancer Angiogenesis Inhibitors Market Size Forecast by Region &nbsp;12.1.1 Global Cancer Angiogenesis Inhibitors Forecast by Region (2026-2031) &nbsp;12.1.2 Global Cancer Angiogenesis Inhibitors Annual Revenue Forecast by Region (2026-2031) &nbsp;12.2 Americas Forecast by Country (2026-2031) &nbsp;12.3 APAC Forecast by Region (2026-2031) &nbsp;12.4 Europe Forecast by Country (2026-2031) &nbsp;12.5 Middle East & Africa Forecast by Country (2026-2031) &nbsp;12.6 Global Cancer Angiogenesis Inhibitors Forecast by Type (2026-2031) &nbsp;12.7 Global Cancer Angiogenesis Inhibitors Forecast by Application (2026-2031) 13 Key Players Analysis &nbsp;13.1 Intas Pharmaceuticals &nbsp;13.1.1 Intas Pharmaceuticals Company Information &nbsp;13.1.2 Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Product Portfolios and Specifications &nbsp;13.1.3 Intas Pharmaceuticals Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.1.4 Intas Pharmaceuticals Main Business Overview &nbsp;13.1.5 Intas Pharmaceuticals Latest Developments &nbsp;13.2 Kyowa Hakko Kirin &nbsp;13.2.1 Kyowa Hakko Kirin Company Information &nbsp;13.2.2 Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Product Portfolios and Specifications &nbsp;13.2.3 Kyowa Hakko Kirin Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.2.4 Kyowa Hakko Kirin Main Business Overview &nbsp;13.2.5 Kyowa Hakko Kirin Latest Developments &nbsp;13.3 Levolta Pharmaceuticals &nbsp;13.3.1 Levolta Pharmaceuticals Company Information &nbsp;13.3.2 Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Product Portfolios and Specifications &nbsp;13.3.3 Levolta Pharmaceuticals Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.3.4 Levolta Pharmaceuticals Main Business Overview &nbsp;13.3.5 Levolta Pharmaceuticals Latest Developments &nbsp;13.4 Mabtech &nbsp;13.4.1 Mabtech Company Information &nbsp;13.4.2 Mabtech Cancer Angiogenesis Inhibitors Product Portfolios and Specifications &nbsp;13.4.3 Mabtech Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.4.4 Mabtech Main Business Overview &nbsp;13.4.5 Mabtech Latest Developments &nbsp;13.5 Marsala Biotech &nbsp;13.5.1 Marsala Biotech Company Information &nbsp;13.5.2 Marsala Biotech Cancer Angiogenesis Inhibitors Product Portfolios and Specifications &nbsp;13.5.3 Marsala Biotech Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.5.4 Marsala Biotech Main Business Overview &nbsp;13.5.5 Marsala Biotech Latest Developments &nbsp;13.6 Neumedicines &nbsp;13.6.1 Neumedicines Company Information &nbsp;13.6.2 Neumedicines Cancer Angiogenesis Inhibitors Product Portfolios and Specifications &nbsp;13.6.3 Neumedicines Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.6.4 Neumedicines Main Business Overview &nbsp;13.6.5 Neumedicines Latest Developments &nbsp;13.7 Genentech &nbsp;13.7.1 Genentech Company Information &nbsp;13.7.2 Genentech Cancer Angiogenesis Inhibitors Product Portfolios and Specifications &nbsp;13.7.3 Genentech Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.7.4 Genentech Main Business Overview &nbsp;13.7.5 Genentech Latest Developments &nbsp;13.8 Five Prime Therapeutics &nbsp;13.8.1 Five Prime Therapeutics Company Information &nbsp;13.8.2 Five Prime Therapeutics Cancer Angiogenesis Inhibitors Product Portfolios and Specifications &nbsp;13.8.3 Five Prime Therapeutics Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.8.4 Five Prime Therapeutics Main Business Overview &nbsp;13.8.5 Five Prime Therapeutics Latest Developments &nbsp;13.9 Fuji Film Kyowa Kirin Biologics &nbsp;13.9.1 Fuji Film Kyowa Kirin Biologics Company Information &nbsp;13.9.2 Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Product Portfolios and Specifications &nbsp;13.9.3 Fuji Film Kyowa Kirin Biologics Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.9.4 Fuji Film Kyowa Kirin Biologics Main Business Overview &nbsp;13.9.5 Fuji Film Kyowa Kirin Biologics Latest Developments &nbsp;13.10 Genexine &nbsp;13.10.1 Genexine Company Information &nbsp;13.10.2 Genexine Cancer Angiogenesis Inhibitors Product Portfolios and Specifications &nbsp;13.10.3 Genexine Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.10.4 Genexine Main Business Overview &nbsp;13.10.5 Genexine Latest Developments &nbsp;13.11 Hetero Drugs &nbsp;13.11.1 Hetero Drugs Company Information &nbsp;13.11.2 Hetero Drugs Cancer Angiogenesis Inhibitors Product Portfolios and Specifications &nbsp;13.11.3 Hetero Drugs Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.11.4 Hetero Drugs Main Business Overview &nbsp;13.11.5 Hetero Drugs Latest Developments &nbsp;13.12 ImClone Systems &nbsp;13.12.1 ImClone Systems Company Information &nbsp;13.12.2 ImClone Systems Cancer Angiogenesis Inhibitors Product Portfolios and Specifications &nbsp;13.12.3 ImClone Systems Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.12.4 ImClone Systems Main Business Overview &nbsp;13.12.5 ImClone Systems Latest Developments &nbsp;13.13 Novartis &nbsp;13.13.1 Novartis Company Information &nbsp;13.13.2 Novartis Cancer Angiogenesis Inhibitors Product Portfolios and Specifications &nbsp;13.13.3 Novartis Cancer Angiogenesis Inhibitors Sales, Revenue, Price and Gross Margin (2020-2025) &nbsp;13.13.4 Novartis Main Business Overview &nbsp;13.13.5 Novartis Latest Developments 14 Research Findings and Conclusion

Report	Global Cancer Angiogenesis Inhibitors Market Growth 2025-2031
Selected License	Multi ID: LPI21240

Buyer Information

Order Summary